MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/blood.2023021579

Медицинская библиотека · Blood · 2024

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.

Othman Jad, Tiong Ing S, O'Nions Jenny, Dennis Mike, Mokretar Katya, Ivey Adam, Austin Michael, Latif Anne-Louise, Amer Mariam, Chan Wei Yee, Crawley Charles, Crolla Francesca, Cross Joe, Dang Ray, Elliot Johnathon, Fong Chun Y, Galli Sofia, Gallipoli Paolo, Hogan Francesca, Kalkur Pallavi, Khan Anjum, Krishnamurthy Pramila, Laurie John, Loo Sun, Marshall Scott, Mehta Priyanka, Murthy Vidhya, Nagumantry Sateesh, Pillai Srinivas, Potter Nicola, Sellar Rob, Taylor Tom, Zhao Rui, Russell Nigel H, Wei Andrew H, Dillon Richard

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Assessment of measurable residual disease (MRD) by quantitative reverse transcription polymerase chain reaction is strongly prognostic in patients with NPM1-mutated acute myeloid leukemia (AML) treated with intensive chemotherapy; however, there are no data regarding its utility in venetoclax-based nonintensive therapy, despite high efficacy in this genotype. We analyzed the prognostic impact of NPM1 MRD in an international real-world cohort of 76 previously untreated patients with NPM1-mutated AML who achieved complete remission (CR)/CR with incomplete hematological recovery following treatment with venetoclax and hypomethylating agents (HMAs) or low-dose cytarabine (LDAC). A total of 44 patients (58%) achieved bone marrow (BM) MRD negativity, and a further 14 (18%) achieved a reduction of ≥4 log10 from baseline as their best response, with no difference between HMAs and LDAC. The cumulative rates of BM MRD negativity by the end of cycles 2, 4, and 6 were 25%, 47%, and 50%, respectively. Patients achieving BM MRD negativity by the end of cycle 4 had 2-year overall of 84% compared with 46% if MRD was positive. On multivariable analyses, MRD negativity was the strongest prognostic factor. A total of 22 patients electively stopped therapy in BM MRD-negative remission after a median of 8 cycles, with 2-year treatment-free remission of 88%. In patients with NPM1-mutated AML attaining remission with venetoclax combination therapies, NPM1 MRD provides valuable prognostic information.

Для цитирования: Othman Jad, Tiong Ing S, O'Nions Jenny, Dennis Mike, Mokretar Katya, Ivey Adam, Austin Michael, Latif Anne-Louise, Amer Mariam, Chan Wei Yee, Crawley Charles, Crolla Francesca, Cross Joe, Dang Ray, Elliot Johnathon, Fong Chun Y, Galli Sofia, Gallipoli Paolo, Hogan Francesca, Kalkur Pallavi, Khan Anjum, Krishnamurthy Pramila, Laurie John, Loo Sun, Marshall Scott, Mehta Priyanka, Murthy Vidhya, Nagumantry Sateesh, Pillai Srinivas, Potter Nicola, Sellar Rob, Taylor Tom, Zhao Rui, Russell Nigel H, Wei Andrew H, Dillon Richard. Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.. Blood. 2024. DOI: 10.1182/blood.2023021579.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.